Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
Open Access
- 11 July 2018
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-11
Abstract
Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating functionally important tissue areas. Achieving complete tumor resection and preserving functionally relevant tissue structures depends on precise identification of tumor-free resection margins during surgery. Fluorescence-guided surgery (FGS), by intraoperative detection of tumor cells using a fluorescent tracer, may guide surgical excision and identify tumor-positive resection margins. Using a literature survey on potential surface molecules followed by immunohistochemical validation, we identified CD44 variant 6 (CD44v6) as a constitutively expressed antigen in the invasion zone of HNSCC lesions. The monoclonal anti-CD44v6 antibody BIWA was labeled with both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111) and dual-modality imaging was applied in a locally invasive tumor mouse model. BIWA accurately detected human HNSCC xenografts in mice with a tumor uptake of 54 ± 11% ID/g and invasion regions with an accuracy of 94%. When dissected under clinical-like conditions, tumor remnants approximately 0.7 mm in diameter consisting of a few thousand cells were identified by fluorescence imaging, resulting in reliable dissection of invasive microregions. These data indicate that CD44v6 is a suitable target for reliable near-infrared detection and FGS of invasive HNSCC lesions in vivo.Keywords
This publication has 40 references indexed in Scilit:
- Expression of COX-2, CD44v6 and CD147 and Relationship with Invasion and Lymph Node Metastasis in Hypopharyngeal Squamous Cell CarcinomaPLOS ONE, 2013
- Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma In Situ with CD44v6-Specific Antibodies in Mice: A Preclinical StudyMolecular Imaging and Biology, 2012
- Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targetsEJNMMI Research, 2011
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- New Strategies for Fluorescent Probe Design in Medical Diagnostic ImagingChemical Reviews, 2009
- Targeting CD44v6 Expressed in Head and Neck Squamous Cell Carcinoma: Preclinical Characterization of an 111In-Labeled Monoclonal AntibodyTumor Biology, 2008
- Quantification of CD44v6 and EGFR Expression in Head and Neck Squamous Cell Carcinomas Using a Single-Dose RadioimmunoassayTumor Biology, 2007
- Safety, Pharmacokinetics, Immunogenicity, and Biodistribution of 186 Re-Labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab( in Patients with Early-Stage Breast CancerCancer Biotherapy and Radiopharmaceuticals, 2004
- Clinicopathologic Significance of Expression of CD44s and CD44v6 Isoforms in Squamous Cell Carcinoma of the Supraglottic LarynxAmerican Journal of Clinical Pathology, 2002
- Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head‐and‐neck cancer xenograftsInternational Journal of Cancer, 2002